Eli Lilly and Laekna will collaborate to develop an obesity drug focusing on weight loss while preserving muscle. Lilly aims to solidify its position in the growing $150 billion obesity market by leveraging Laekna's experimental drug, LAE102, which has shown promising results in lab studies.